Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03038399
• Date of registration: 30/01/2017
• Prospective Registration: Yes
• Primary sponsor: ReveraGen BioPharma, Inc.
• Public title: Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
• Scientific title: A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
• Date of first enrolment: February 2, 2017
• Target sample size: 46
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03038399
• Study type: Interventional
• Study design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Australia, Canada, Israel, Sweden, United Kingdom, United States

Contacts

• Name: Paula R Clemens, MD
• Affiliation: University of Pittsburgh

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Subject's parent or legal guardian has provided written informed consent and HIPAA
authorization (if applicable) prior to any VBP15-LTE long-term extension
study-specific procedures;

2. Subject has previously completed study VBP15-003 up to and including the Week 24 Final
assessments, prior to enrolling in the VBP15-LTE study at the conclusion of the
VBP15-003 Week 24 Visit [Note: if entering the dose-tapering period, subject is
enrolling within 8 weeks after the VBP15-003 final visit following dose-tapering]; and

3. Subject and parent/guardian are willing and able to comply with scheduled visits,
study drug administration plan, and study procedures.

Exclusion Criteria:

1. Subject had a serious or severe adverse event in study VBP15-003 that, in the opinion
of the Investigator, was probably or definitely related to vamorolone use and
precludes safe use of vamorolone for the subject in this long-term extension study;

2. Subject has current or history of major renal or hepatic impairment, diabetes mellitus
or immunosuppression;

3. Subject has current or history of chronic systemic fungal or viral infections;

4. Subject has used mineralocorticoid receptor agents, such as spironolactone,
eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium),
mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study
medication;

5. Subject has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac
abnormality on investigation would not be exclusionary];

6. Subject is currently being treated or has received previous treatment with oral
glucocorticoids or other immunosuppressive agents [Notes: Past transient use of oral
glucocorticoids or other oral immunosuppressive agents for no longer than 3 months
cumulative, with last use at least 3 months prior to first dose of study medication,
will be considered for eligibility on a case-by-case basis. Inhaled and/or topical
glucocorticoids prescribed for an indication other than DMD are permitted but must be
administered at stable dose for at least 3 months prior to study drug administration];

7. Subject has used idebenone within 4 weeks prior to the first dose of study medication;

8. Subject has an allergy or hypersensitivity to the study medication or to any of its
constituents;

9. Subject has severe behavioral or cognitive problems that preclude participation in the
study, in the opinion of the Investigator;

10. Subject has previous or ongoing medical condition, medical history, physical findings
or laboratory abnormalities that could affect safety, make it unlikely that treatment
and follow-up will be correctly completed or impair the assessment of study results,
in the opinion of the Investigator

11. Subject is currently taking any investigational drug, or has taken any investigational
drug other than vamorolone within 3 months prior to the start of study treatment.

Note: Subjects may be re-evaluated if ineligible due to a transient condition which would
prevent the subject from participating.



Age minimum: 4 Years
Age maximum: 7 Years
Gender: Male

Health Condition(s) or Problem(s) studied

Duchenne Muscular Dystrophy

Intervention(s)

Drug: Vamorolone 0.75 mg/day/day

Drug: Vamorolone 2.0 mg/day/day

Drug: Vamorolone 0.25 mg/day/day

Drug: Vamorolone 6.0 mg/day/day

Primary Outcome(s)

Body size as measured by body mass index (BMI) z-score [Time Frame: 24 months]

Muscle function measured by Time to Stand Test (TTSTAND) [Time Frame: 24 weeks]

Number of participants with treatment-related adverse events as assessed by CTCAE Version 4.03 [Time Frame: 24 months]

Secondary Outcome(s)

Serum pharmacodynamics biomarkers measured by levels of testosterone [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of 11-deoxycortisol [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of 17- hydroxyprogesterone [Time Frame: 24 months]

Muscle function measured by Six-minute Walk Test (6MWT) [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of osteocalcin [Time Frame: 24 months]

Muscle strength measured by Quantitative Muscle Testing (QMT) [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of cortisol [Time Frame: 24 months]

Muscle function measured by North Star Ambulatory Assessment (NSAA) [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of PINP [Time Frame: 24 months]

Muscle function measured by Time to Run/Walk 10 Meters Test (TTRW) [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of insulin [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of glucose [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of CTX [Time Frame: 24 months]

Muscle function measured by Time to Climb Test (TTCLIMB) [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of ACTH [Time Frame: 24 months]

Serum pharmacodynamics biomarkers measured by levels of corticosterone [Time Frame: 24 months]

Secondary ID(s)

VBP15-LTE

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

University of Pittsburgh

Cooperative International Neuromuscular Research Group